Panagora Asset Management Inc. lowered its stake in NewLink Genetics Corp (NASDAQ:NLNK) by 71.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 193,260 shares of the biotechnology company’s stock after selling 477,815 shares during the quarter. Panagora Asset Management Inc.’s holdings in NewLink Genetics were worth $286,000 at the end of the most recent reporting period.
Separately, Requisite Capital Management LLC bought a new position in NewLink Genetics in the second quarter valued at approximately $185,000. 29.32% of the stock is currently owned by hedge funds and other institutional investors.
NLNK traded up $0.01 during trading on Friday, reaching $1.94. The company had a trading volume of 507 shares, compared to its average volume of 210,522. The company has a debt-to-equity ratio of 0.08, a current ratio of 12.77 and a quick ratio of 12.77. NewLink Genetics Corp has a 12 month low of $1.28 and a 12 month high of $2.68. The business’s fifty day moving average price is $1.62 and its 200 day moving average price is $1.67. The company has a market cap of $72.75 million, a P/E ratio of -1.34 and a beta of 1.21.
NewLink Genetics (NASDAQ:NLNK) last announced its quarterly earnings results on Tuesday, July 30th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.29) by $0.02. NewLink Genetics had a negative net margin of 6,587.56% and a negative return on equity of 34.44%. The firm had revenue of $0.15 million for the quarter. As a group, sell-side analysts predict that NewLink Genetics Corp will post -0.03 EPS for the current fiscal year.
A number of research analysts have weighed in on the stock. Zacks Investment Research raised shares of NewLink Genetics from a “hold” rating to a “buy” rating and set a $2.00 price target on the stock in a research note on Saturday, August 3rd. ValuEngine raised shares of NewLink Genetics from a “sell” rating to a “hold” rating in a research note on Thursday, August 1st.
NewLink Genetics Profile
NewLink Genetics Corporation, a late clinical-stage immuno-oncology company, focuses on discovering and developing novel immunotherapeutic products for the treatment of patients with cancer. It is developing Indoximod, an indoleamine-2, 3-dioxygenase (IDO) pathway inhibitor that is in clinical development in combination with other cancer therapeutics for patients with diffuse intrinsic pontine glioma, pediatric brain tumors, acute myeloid leukemia, and melanoma.
Further Reading: How does new data get added to a blockchain?
Want to see what other hedge funds are holding NLNK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for NewLink Genetics Corp (NASDAQ:NLNK).
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.